Cagrilintide Dosage: Doses Studied, Units and Chart
What doses of Cagrilintide have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 5 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- 159-195 h (with semaglutide 2.4 mg co-administered)
- subcutaneous, in people · Lancet 2021, PMID 33894838
- Vial sizes sold
- 2.5 mg, 5 mg, 10 mg
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 0.6 mg (renal study) or 0.9 mg (hepatic study), single dose | single dose · subcutaneous · single dose | Human controlled trial | Clinical pharmacokinetics 2026, PMID 42228334 |
| dose escalated to 4.5 mg (placebo arm received single oral moxifloxacin 400 mg as positive control) | once weekly · subcutaneous | Human RCTn = 105 | Diabetes, obesity & metabolism 2024, PMID 39279639 |
| 0.3, 0.6, 1.2, 2.4 or 4.5 mg (vs liraglutide 3.0 mg daily or placebo) | once weekly · subcutaneous · 26 weeks plus 6 weeks follow-up | Human RCT | Lancet 2021, PMID 34798060 |
| cagrilintide 0.16-4.5 mg plus semaglutide 2.4 mg, vs placebo plus semaglutide | once weekly · subcutaneous · 20 weeks (16 weeks co-escalation, 4 weeks at target dose) | Human RCTn = 96 | Lancet 2021, PMID 33894838 |
| 3 nmol/kg | once daily · subcutaneous · 3 weeks | Animal · mouse (not a human result) | EBioMedicine 2025, PMID 40609154 |
Dose to syringe units
For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.
- 0.25 mg
- 5 u
- 0.5 mg
- 10 u
- 1 mg
- 20 u
- 1.5 mg
- 30 u
- 2 mg
- 40 u
- 2.5 mg
- 50 u
Before anyone considers it
- Cagrilintide is investigational and not approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Common questions
How many units is 1 mg of Cagrilintide?
It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 1 mg is 20 units on a U-100 syringe. Use the calculator for other mixes.
Is Cagrilintide FDA approved?
No. Cagrilintide is investigational (investigational (cagrisema component)) and not approved for any use.
More on Cagrilintide
Side effectsWhat labels and studies report, and what is unknown.CalculatorVial, water and dose to syringe units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.Half-lifeWhat is measured, by route, and what is not.
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
- 4Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
- 5Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
- 6Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
- 7Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.EBioMedicine · 2025PMID 40609154Accessed 2 Oct 2026
Found an error? Report a correction.